GTJA Leads $45M Round In Chinese Antibody Drug Developer Akeso

Li Dongmei
August 29, 2017 — 12:22 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Akeso antibody biotech China chinese Factory GTJA guangdong healthcare human resources investment manufacturing pharmaceutical shenzhen Shenzhen capital group technology venture capital

Related News:

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Chinese Generative AI Startups Secure Substantial Funding in Race to Replicate OpenAI’s Success

November 13, 2023 — 23:55

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

Reports Indicate NVIDIA Tailoring Specialized Chips for China’s Market

November 9, 2023 — 23:26

Kai-Fu Lee’s AI Firm 01.AI Hits Unicorn Status with Alibaba Cloud-Led Funding

November 7, 2023 — 00:55

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

ByteDance Invested In 52 Deals With Total Deal Value Of $6.4B: TikTok Parent Company’s Investments, M&A, Strategic Deals In One Chart 2019-2022

April 29, 2022 — 01:44

China’s Venture Mega-Deals 2019 to 2022 In One Chart: Can It Last?

April 15, 2022 — 00:30